Uncategorized

Clairvoyant’s Section 2 Psilocybin Therapy Trial for Alcohol Use Dysfunction Obtains Regulatory Approval and Initiates 1st Clinical Web site in Finland

VANCOUVER, BC / ACCESSWIRE / October 13, 2022 / Clairvoyant Therapeutics (“Clairvoyant”), a Canadian biotech company centered on the pattern of psychedelic drug therapies for the treatment of dependancy, is fully pleased to enlighten it has bought regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Section 2 clinical trial investigating psilocybin, a compound display cloak in psychedelic mushrooms, for the treatment of alcohol utilize dysfunction (AUD) in Finland.

Clairvoyant’s randomized, controlled, clinical trial, CLA-PSY-201, will take into story the safety and efficacy of a 25 mg synthetic psilocybin pill versus placebo, with Motivational Enhancement Therapy (MET). Basically based totally on the FIMEA approval, Clairvoyant has initiated the first of 4 planned trial net sites in Finland. Earlier this year, Clairvoyant additionally presented it had bought Well being Canada approval to proceed with the trial in Canada and a extensive selection of doable patients non-public lately entered the screening course of.

“We’re pleased to non-public approval to transfer forward with our trial in a 2nd country and non-public ourfirst plot initiated there,” mentioned Damian Kettlewell, CEO, Clairvoyant. “We now non-public had steady pastime from patients about participating in our Canadian net sites and are furious to begin the recruitment of patients in Finland. Most importantly, we are anxious to continue adding to our world thought of how psilocybin can support these residing with AUD.”

Increase for the utilize of psilocybin as a therapeutic agent is growing. Lately printed data showed that two doses of psilocybin minimize heavy drinking by 83 per cent on common among heavy drinkers when blended with psychotherapy.[i] These encouraging clinical results linked to the utilize of psilocybin for the treatment of AUD support validate Clairvoyant’s bear clinical formulation.

Clairvoyant goals to be the first company on this planet to steady market authorization for psilocybin in Europe, the UK, and Canada to reduction patients residing with AUD. The corporate is on song to execute acclaim for psilocybin treatment for AUD in the EU, UK & Canada in 2026.

About CLA-PSY-201

CLA-PSY-201 is a clinical trial that compares 25 mg of synthetic pharmaceutical grade oral psilocybin pill to placebo in the context of Motivational Enhancement Therapy (MET). The clinical trial is initiating roughly 15 clinical net sites in Canada and Europe. Clairvoyant’s extensive therapist coaching program is rolling out at every clinical plot in declare to ensure the supreme expert and ethical requirements. An intervening time data readout is anticipated in mid-2023.

About Alcohol Use Dysfunction

Basically based totally on the World Well being Group, 283 million other folks prone 15 years and older are at risk of alcohol utilize dysfunction.[ii] Globally, mortality from alcohol consumption is elevated than from diseases akin to tuberculosis, HIV/AIDS, and diabetes.[ii]

About Clairvoyant

Clairvoyant Therapeutics is a Canadian biotech company essentially based by an distinctive crew with a proven clinical display screen file and deep drug pattern trip bringing contemporary pills to market. Clairvoyant is working a multi-country multi-plot Section 2b psilocybin treatment randomized protect a watch on trial for alcohol utilize dysfunction (AUD).

Clairvoyant is committed to assembly the supreme requirements of verified social and environmental efficiency, public transparency and lawful accountability to balance profit and reason and is a pending B Company Certification. Clairvoyant is a member of Lifestyles Science BC and Biotechnology Innovation Group (BIO).

Be taught extra at www.clairvoyantrx.com and apply the Company on LinkedIn and Twitter.

-30-

For extra files:

Media requests:

Marlo Taylor

[email protected]

Corporate contact:

Damian Kettlewell

[email protected] [i] Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Ingesting Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Dysfunction: A Randomized Clinical Trial. JAMA Psychiatry. Printed online August 24, 2022. doi: 10.1001/jamapsychiatry.2022.2096

[ii] World Well being Group. World alcohol action thought 2022-2030 to pork up implementation of the World Plan to Decrease the Insensible Use of Alcohol First draft. June 2021.

SOURCE: Clairvoyant Therapeutics

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button